ATOX

What ATOX does

ATOX Corporation is a privately held Japanese nuclear engineering services company founded in September 1980 and headquartered in Tokyo. The company was the first private firm in Japan to undertake radioactive contamination removal work at nuclear facilities and has accumulated over four decades of integrated maintenance, decommissioning, and radiation management capabilities. Its core business spans four segments: nuclear facility-related engineering (plant construction, decommissioning, facility management, and radiation management), Fukushima reconstruction services (decommissioning work, equipment installation, environmental facilities, and regional reconstruction), a life sciences division applying radiation technology to medical devices and radioisotope products, and ancillary equipment/goods sales and radiation safety education. The firm operates an extensive footprint including a 9,600m² Technology Development Center in Kashiwa, the ESCA engineering service hub established in 2020, the Fukushima Reconstruction Branch with an attached Technical Training Center, and embedded operations offices at major nuclear plant sites across Japan.

ATOX generates revenue through professional services contracts with nuclear power plant operators and government agencies, hardware sales of proprietary and distributed medical devices, and training and certification fees. Its technology stack includes remote-controlled robotics (RACCOON, dual-arm systems) for high-radiation decommissioning environments, the world's first helmet-type PET imaging device (Vrain) developed with QST, MCCCE lithium-7 enrichment technology aimed at reducing Russian import dependence for PWR coolants, and exclusive Japanese distribution rights for IRE ELiT's Galli Eo 68Ge/68Ga generator used in prostate cancer PET diagnostics. Go-to-market is enterprise field sales with a nationwide network (Tokyo, Osaka, Tokai sales offices plus embedded site offices) and long-term direct contracts with utilities including TEPCO and government entities such as JAEA and QST.

The customer base is concentrated among Japanese nuclear utilities, government research bodies, and pharmaceutical companies. ATOX holds certified radiation management handbook issuance authority under Japan's national dose registration system, a regulatory credential that creates structural barriers to entry. In 2021, the company acquired the nuclear business operations of Kawasaki Heavy Industries, substantially scaling its engineering workforce and technical capabilities. The firm is privately held with no disclosed institutional investors and is led by President Yoshikazu Yaguchi.

Name

ATOX

Legal name

株式会社アトラック

Website

https://atox.co.jp

Company type

Private

Founded year

1980

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

ATOX Corporation is a privately held Japanese nuclear engineering services firm that provides maintenance, decommissioning, and radiation management to nuclear utilities, plus medical imaging devices and radioisotope products to hospitals and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Nuclear Facility Engineering Services

NAICS

Engineering Services (54133), Irradiation Apparatus Manufacturing (334517), Environmental Consulting Services (541620)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Services-Commercial Physical & Biological Research (8731), X-Ray Apparatus & Tubes & Related Irradiation Apparatus (3844)

akta.pro primary industry

Radiation Protection & Health Physics (ALARA, Dosimetry, Contamination Control) (EUAKABAH)

akta.pro secondary industries

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA), Nuclear Materials Testing, Assay & Characterization Services (NDA/NDE, radiochemistry, materials analysis) (EUAKAIAL), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology) (EUAKAIAD)

Keywords

• Nuclear facility engineering
• Nuclear decommissioning services
• Radiation management
• Fukushima decommissioning
• Nuclear medicine devices

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices14 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Nuclear Facility Engineering Services: Comprehensive maintenance, decommissioning, radiation management, and plant engineering services for nuclear facilities across Japan. Revenue generated through long-term service contracts with nuclear power operators and one-time project contracts for decommissioning and plant modification work.
2. Equipment and Goods Sales: Sales of nuclear-related equipment (remote robots, measurement instruments) and general goods, plus distribution of medical devices including the Vrain PET system and 68Ge/68Ga generators.
3. Medical Device Sales: Sale of medical devices including the Vrain head-specific PET system, Galli Eo 68Ge/68Ga generators, and Digital Radiography AX-α series. Also includes accelerator maintenance services for pharmaceutical companies and hospitals.
4. Radiation Safety Education: Provides radiation safety education programs (学科教育) at multiple offices. Revenues generated from training fees. Programs include radiation worker education (放射性同位元素等の規制に関する法律に基づく教育) and special education under ionizing radiation regulations.
5. Fukushima Reconstruction Services: Decommissioning work, equipment installation, environmental facilities, radiation analysis, regional reconstruction support, and warehousing services in the Fukushima region.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

ATOX provides comprehensive nuclear facility engineering services for Japanese power plant operators, including equipment and plant construction, routine facility maintenance, radiation management, and decommissioning work (with a dedicated focus on Fukushima Daiichi remediation). Beyond nuclear services, the company operates a Life Sciences division that develops and sells the Vrain head-specific PET device (co-developed with QST), digital radiography AX-α detectors, Galli Eo 68Ge/68Ga radioisotope generators, stable isotopes, and related medical and pharmaceutical R&D, including 68Ga-PSMA prostate cancer diagnostics and 224Ra/212Pb generator research with RIKEN.

Differentiator

Problem solved

Functional benefit

Brands

• ATOX: Company brand name and trading name
• Vrain
• Galli Eo
• ESCA (Engineering Service Center of ATOX)
• AX-α series

Products and services

• Nuclear Facility Equipment and Plant Engineering (設備・プラント工事)

Quantifiable outcome

• 15-month quality validation of Galli Eo 68Ge/68Ga generator exceeding the 12-month validity period with maintained quality
• +2 more outcomes

Named customers9 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• 東京大学 (Tokyo University)coreStrategic or Co-development Partner · 1 January 2026ATOX and Tokyo University Graduate School of Engineering established a social collaboration research program 'Radiation Applied Technology Innovation' (January 1, 2026 – December 31, 2028). Research focuses on understanding scatter radiation physics to develop social infrastructure diagnostic technologies using high-energy X-rays. Led by Professor Hasegawa Shuichi (東京大学)
• フュージョンエネルギー産業協議会 / 一般社団法人J-Fusion (Fusion Energy Industry Council)minorStrategic or Co-development Partner · 29 March 2024ATOX participates as a founding board member (発起人企業, 理事企業) in the Japan Fusion Energy Industry Council (J-Fusion), established in March 2024, signaling involvement in future fusion energy business opportunities.
• バイエル薬品株式会社 (Bayer Pharmaceutical)coreStrategic or Co-development Partner · 17 May 2023ATOX supplies IRE ELiT's 68Ge/68Ga generator 'Galli Eo' to Bayer Pharmaceutical for their prostate cancer clinical trials in Japan. This supply contract was signed in May 2023.
• AMS企画株式会社 (AMS Kikaku)minorStrategic or Co-development Partner · 27 January 2022ATOX and AMS Kikaku signed a joint development agreement on January 27, 2022 for a 68Ga-PSMA-11 automatic synthesis device using the 68Ge/68Ga generator for prostate cancer diagnosis. The companies aim to obtain regulatory approval (pharmaceutical/medical device approval) for the synthesis device.
• ANADEC (Joint Venture with Orano)coreStrategic or Co-development Partner · 26 March 2021ANADEC is a joint venture between ATOX and French nuclear company Orano. The JV was revised in July 2019. ANADEC handles Japanese D&D (decommissioning and decontamination) operations and received a Minister of Economy, Trade and Industry Certificate of Appreciation for participation in TEPCO Fukushima Daiichi Units 2-3 reactor containment vessel internal surveys.
• 川崎重工業株式会社 (Kawasaki Heavy Industries)coreStrategic or Co-development Partner · 24 November 2020ATOX acquired Kawasaki Heavy Industries' nuclear business operations through a formal transfer agreement signed in November 2020, with the final contract signed March 26, 2021. This acquisition significantly expanded ATOX's nuclear engineering capabilities and workforce, adding technologies and know-how from Kawasaki's nuclear operations.
• テリックスファーマジャパン株式会社 (Telix Pharma Japan)coreStrategic or Co-development Partner · 16 July 2020ATOX signed an agreement to supply IRE ELiT's 68Ge/68Ga generator 'Galli Eo' to Telix Pharma Japan for use in their Phase I clinical trial of the 68Ga-PSMA-11 prostate cancer imaging kit. Telix Pharma Japan is a 100% subsidiary of Australian Telix Pharmaceuticals (ASX:TLX).
• 北海道大学 / 大阪大学 / 住友重機械工業株式会社 (Hokkaido University, Osaka University, Sumitomo Heavy Industries)coreStrategic or Co-development Partner · 31 October 2018Joint research agreement for 68Ga-PSMA pharmaceutical regulatory approval signed October 31, 2018. ATOX handles quality testing for the Galli Eo generator as part of preclinical studies, physician-initiated clinical trials, and medical device approval for the 68Ga-PSMA synthesis system. ATOX serves as overall project coordinator for MCCCE Li-7 enrichment technology with a 9-member consortium led by Osaka University.
• IRE ELiT社 (Belgium)coreChannel Partner/ Reseller/ Distributor · 27 February 2018ATOX signed an exclusive distribution agreement for IRE ELiT's 68Ge/68Ga generator 'Galli Eo' in Japan in February 2018. IRE ELiT, a subsidiary of Belgian radioharma major IRE, manufactures the generator which can produce Ga-68 without cyclotrons or nuclear reactors. The product is used for 68Ga-PSMA prostate cancer PET diagnostics.
• 国立研究開発法人理化学研究所 (RIKEN)coreStrategic or Co-development Partner · 30 November 2017ATOX and RIKEN signed a joint research agreement in November 2017 to develop a Lead-212 (212Pb) generator for use in alpha-ray internal radioisotope therapy. The project was one of several selected for the JST OPERA program in FY2017, with a planned 5-year duration. RIKEN's 80+ years of radioisotope research expertise complements ATOX's nuclear facility operations experience.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Toshiba Energy Systems & Solutions: Subsidiary of Toshiba providing nuclear plant equipment, services, and fuel. Comparable to ATOX in the Japanese nuclear services and maintenance market, but operating as part of a much larger diversified energy portfolio.
• Westinghouse Electric Company: US-headquartered nuclear power plant designer and global services provider. Competes with ATOX in nuclear plant services and fuel cycle support, but at vastly larger scale as a vertically integrated nuclear OEM with global operations.
• Hitachi-GE Nuclear Energy: Japan-headquartered joint venture between Hitachi and GE Vernova supplying nuclear power plant equipment, services, and fuel cycle support. Overlaps with ATOX in plant engineering and maintenance for Japanese reactors but at much broader scale and as part of an integrated BWR portfolio.
• Jacobs Solutions: Global engineering services firm with a significant nuclear, decommissioning, and environmental remediation practice. Comparable to ATOX in nuclear engineering consulting and decommissioning project delivery, but as part of a much larger professional services platform.
• AtkinsRéalis (formerly SNC-Lavalin): Canadian engineering and nuclear services firm with a dedicated Nuclear segment covering CANDU reactor services, decommissioning, and waste management. Comparable to ATOX in nuclear engineering services and decommissioning project execution, at significantly larger enterprise scale.

Direct peers

• Babcock & Wilcox: US-based provider of nuclear plant services, environmental remediation, and decommissioning. Operates a similar nuclear-focused engineering and services portfolio to ATOX and is a relevant scale and geographic peer in commercial nuclear services.
• Veolia Nuclear Solutions (formerly Kurion): Veolia's nuclear subsidiary specializing in radiological waste treatment, decommissioning, and site remediation. Direct peer to ATOX's Fukushima reconstruction and decontamination business, particularly in remote-handled waste processing and radiation management.
• Orano: France-based nuclear services and decommissioning major. Orano is ATOX's joint venture partner in ANADEC for Japanese D&D work, making it the most directly comparable peer across nuclear facility engineering, decommissioning, and radiation management services.
• Studsvik: Swedish nuclear services company providing decommissioning, waste management, and engineering services to commercial and research reactors globally. Closely comparable business model to ATOX's nuclear facility maintenance, decommissioning, and radiation analysis service lines.

Others

• IRE ELiT: Belgian radiopharmaceutical subsidiary of IRE that manufactures the Galli Eo 68Ge/68Ga generator which ATOX exclusively distributes in Japan. Not a direct competitor but a key supplier partner in ATOX's life sciences business and a comparable specialized radiopharma/nuclear medicine player.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ATOX_official
• Facebookfacebook.com/atox.jp

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ATOX